X4 Pharmaceuticals Statistics
Share Statistics
X4 Pharmaceuticals has 170.55M shares outstanding. The number of shares has increased by 0.72% in one year.
| Shares Outstanding | 170.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 117.85M |
| Failed to Deliver (FTD) Shares | 862 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 11.42M, so 6.7% of the outstanding shares have been sold short.
| Short Interest | 11.42M |
| Short % of Shares Out | 6.7% |
| Short % of Float | 9.75% |
| Short Ratio (days to cover) | 8.64 |
Valuation Ratios
The PE ratio is -1.47 and the forward PE ratio is -0.87.
| PE Ratio | -1.47 |
| Forward PE | -0.87 |
| PS Ratio | 0 |
| Forward PS | 2.5 |
| PB Ratio | 2.92 |
| P/FCF Ratio | -1.54 |
| PEG Ratio | n/a |
Enterprise Valuation
X4 Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 1.09.
| Current Ratio | 5.34 |
| Quick Ratio | 5.34 |
| Debt / Equity | 1.09 |
| Total Debt / Capitalization | 52.14 |
| Cash Flow / Debt | -1.73 |
| Interest Coverage | -18.61 |
Financial Efficiency
Return on equity (ROE) is -1.98% and return on capital (ROIC) is -98.38%.
| Return on Equity (ROE) | -1.98% |
| Return on Assets (ROA) | -0.69% |
| Return on Capital (ROIC) | -98.38% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -796.59K |
| Employee Count | 127 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 78.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -10.35% in the last 52 weeks. The beta is 0.39, so X4 Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -10.35% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 58.45 |
| Average Volume (20 Days) | 3.01M |
Income Statement
In the last 12 months, X4 Pharmaceuticals had revenue of $0 and earned -$101.17M in profits. Earnings per share was $-0.57.
| Revenue | 0 |
| Gross Profit | -2.00M |
| Operating Income | -107.52M |
| Net Income | -101.17M |
| EBITDA | -107.52M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.57 |
Balance Sheet
The company has $99.22M in cash and $58.28M in debt, giving a net cash position of $40.94M.
| Cash & Cash Equivalents | 99.22M |
| Total Debt | 58.28M |
| Net Cash | 40.94M |
| Retained Earnings | -477.90M |
| Total Assets | 178.16M |
| Working Capital | 113.71M |
Cash Flow
In the last 12 months, operating cash flow was -$96.51M and capital expenditures -$60.00K, giving a free cash flow of -$96.57M.
| Operating Cash Flow | -96.51M |
| Capital Expenditures | -60.00K |
| Free Cash Flow | -96.57M |
| FCF Per Share | -0.54 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
XFOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -89.06% |
| FCF Yield | -89.1% |
Analyst Forecast
The average price target for XFOR is $4, which is 525% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 525% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 14, 2019. It was a backward split with a ratio of 1:6.
| Last Split Date | Mar 14, 2019 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -4.93 |
| Piotroski F-Score | 2 |